trending Market Intelligence /marketintelligence/en/news-insights/trending/rUDxQpyEHbEx1BFEVhn0Gg2 content esgSubNav
In This List

Arcadia Biosciences Q4 loss widens YOY

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Optimism abounds in Indian online video industry

Blog

2022 broadband forecast shifts to market share battle with intense competition


Arcadia Biosciences Q4 loss widens YOY

Arcadia Biosciences Inc. said its fourth-quarter normalized net income came to a loss of $1.06 per share, compared with the S&P Capital IQ consensus estimate of a loss of $1.40 per share.

The per-share loss narrowed 61.9% year over year from $2.78.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of $2.3 million, compared with a loss of $287,500 in the prior-year period.

The normalized profit margin fell to negative 173.6% from negative 10.3% in the year-earlier period.

Total revenue declined 51.9% on an annual basis to $1.3 million from $2.8 million, and total operating expenses rose 85.0% on an annual basis to $5.4 million from $2.9 million.

Reported net income came to a loss of $3.9 million, or a loss of $1.75 per share, compared to a loss of $3.6 million, or a loss of $35.15 per share, in the year-earlier period.

For the year, the company's normalized net income totaled a loss of $7.90 per share, compared with the S&P Capital IQ consensus normalized EPS estimate of a loss of $9.33.

EPS was a loss of $100.52 in the prior year.

Normalized net income was a loss of $11.3 million, compared with a loss of $10.4 million in the prior year.

Full-year total revenue declined 22.5% year over year to $5.4 million from $7.0 million, and total operating expenses increased on an annual basis to $21.0 million from $20.6 million.

The company said reported net income came to a loss of $20.7 million, or a loss of $14.52 per share, in the full year, compared with a loss of $22.1 million, or a loss of $214.21 per share, the prior year.